Connect
MJA
MJA

Remaining measles challenges in Australia

David N Durrheim, Heath Kelly, Mark J Ferson and David Featherstone
Med J Aust 2007; 187 (3): 181-184.
  • David N Durrheim1
  • Heath Kelly2,3
  • Mark J Ferson4,5
  • David Featherstone6

  • 1 Hunter New England Population Health, Hunter New England Area Health Service, Newcastle, NSW.
  • 2 Epidemiology Unit, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC.
  • 3 School of Population Health, University of Melbourne, Melbourne, VIC.
  • 4 Public Health Unit, South Eastern Sydney and Illawarra Area Health Service, Wollongong, NSW.
  • 5 School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW.
  • 6 Vaccine-Preventable Disease Laboratory Network, Expanded Programme for Immunization, World Health Organization, Geneva, Switzerland.


Acknowledgements: 

We thank Dr Michaela Riddell, National Health and Medical Research Council Sidney Sax Fellow, and Senior Laboratory Epidemiologist, Victorian Infectious Diseases Reference Laboratory, for constructive comments on a draft of this manuscript.

Competing interests:

None identified.

  • 1. Tobin S, Kelly H. Measles encephalitis in Victoria: down but not out. Aust N Z J Public Health 1999; 23: 443.
  • 2. Anderson RM, May RM. Infectious diseases of humans. Dynamics and control. Oxford: Oxford University Press, 1992: 70.
  • 3. Gidding HF, Wood J, MacIntyre CR, et al. Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine 2007; 25: 3574-3580.
  • 4. Strebel P, Cochi S, Grabowsky M, et al. The unfinished measles immunization agenda. J Infect Dis 2003; 187 Suppl 1: S1–S7.
  • 5. Communicable Diseases Report for New South Wales for March and April 2006. N S W Public Health Bull 2006; 17: 88–94.
  • 6. Gidding HF. The impact of Australia’s measles control programme over the past decade. Epidemiol Infect 2005; 133: 99-105.
  • 7. Wood DL, Brunell PA. Measles control in the United States: problems of the past and challenges for the future. Clin Microbiol Rev 1995; 8: 260-267.
  • 8. Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccines — a longitudinal study. Vaccine 2006; 24: 2594-2601.
  • 9. Riddell MA, Lynch P, Jin L, Chibo D. Measles case imported from Europe to Victoria, Australia, March 2006. Euro Surveill 2006; 11: E060518.2.
  • 10. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004; 189 Suppl 1: S4-S16.
  • 11. Lambert SB, Kelly HA, Andrews RM, et al. Enhanced measles surveillance during an interepidemic period in Victoria. Med J Aust 2000; 172: 114-118. <MJA full text>
  • 12. Weber DJ, Cohen MS, Fine J-D. The acutely ill patient with fever and rash. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious disease. 5th ed. Philadelphia: Churchill Livingstone, 2000: 633-650.
  • 13. Scott LA, Stone MS. Viral exanthems. Dermatol Online J 2003; 9: 4.
  • 14. Ferson MJ, Young LC, Robertson PW, Whybin LR. Difficulties in the clinical diagnosis of measles: proposal for modified clinical case definition. Med J Aust 1995; 163: 364-366.
  • 15. Wang YJ, Andrews RM, Lambert SB. Measles surveillance in Victoria, Australia. Bull World Health Organ 2006; 84: 105-111.
  • 16. Dayan GH, Ortega-Sanchez IR, LeBaron CW, Quinlisk MP; Iowa Measles Response Team. The cost of containing one case of measles: the economic impact on the public health infrastructure — Iowa, 2004. Pediatrics 2005: 116: e1-e4.
  • 17. Monitoring the interruption of indigenous measles transmission, Cape Town meeting, 14 October 2003. Wkly Epidemiol Rec 2004; 79: 70-72.
  • 18. Kelly H, Leydon J. Outbreaks caused by parvovirus B19. Euro Surveill 2005; 10: E1-E2.
  • 19. Dietz V, Rota J, Izurieta H, et al. The laboratory confirmation of suspected measles cases in settings of low measles transmission: conclusions from the experience in the Americas. Bull World Health Organ 2004; 82: 852-857.
  • 20. Jenkin GA, Chibo D, Kelly H, et al. What is the cause of rash in a child following measles–mumps–rubella vaccination? Med J Aust 1999; 171: 194-197.
  • 21. Riddell M, Chibo D, Kelly HA, et al. Investigation of optimal specimen type and sampling time for the detection of measles virus RNA during a measles epidemic. J Clin Microbiol 2001; 39: 375-376.
  • 22. Featherstone D, Brown D, Sanders R. Development of the Global Measles Laboratory Network. J Infect Dis 2003; 187 Suppl 1: S264-S269.
  • 23. National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing, 2003: 155. http://www9.health.gov.au/immhandbook/ (accessed Jun 2007).
  • 24. Ferson MJ, Young LC, Robertson PW, Whybin LR. Difficulties in clinical diagnosis of measles: proposal for modified clinical case definition. Med J Aust 1995; 163: 364-366.
  • 25. National Health and Medical Research Council. Staying healthy in child care. Preventing infectious diseases in child care. 4th ed. Canberra: NHMRC, 2005: 8. http://www.nhmrc.gov.au/publications/synopses/_files/ch43.pdf (accessed Jun 2007).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.